Lymphoma Trial Achieves 66% Objective Response Rate
Marker Therapeutics announced on March 18, 2026, that its lead T cell therapy, MT-601, demonstrated significant efficacy in a Phase 1 trial. In the APOLLO study involving patients with relapsed non-Hodgkin lymphoma, the treatment achieved a 66% objective response rate, with 8 of 12 participants responding. Notably, 50% of patients experienced a complete response, with these effects proving durable for a period ranging from 3 to 24 months. The therapy also maintained a favorable safety profile across all dose levels, reporting no dose-limiting toxicities.
Financials Show Cash Runway Through Q4 2026
In its year-end 2025 financial results, Marker reported cash, cash equivalents, and restricted cash of $17 million. The company stated this position is sufficient to fund its operating expenses through the fourth quarter of 2026. For the year ending December 31, 2025, Marker's net loss increased to $12.2 million from $10.7 million in 2024. During the same period, research and development expenses were reduced to $11.8 million from $13.5 million in the prior year, while general and administrative costs remained flat at $4.2 million.
Pipeline Expands with Pancreatic Cancer Focus
Beyond the lymphoma results, Marker is advancing its multi-antigen T cell platform into solid tumors. The company highlighted recent research from Baylor College of Medicine, published in Nature Medicine in January 2026, which showed promising results for the technology in pancreatic cancer. Building on this, Marker expects to launch a company-sponsored clinical program for pancreatic cancer in the second quarter of 2026. This timeline coincides with an anticipated data update from the ongoing APOLLO lymphoma study, positioning the next several months as a critical period for the company.
Looking ahead, we expect continued clinical execution across our programs... which we believe positions the next 12 to 18 months as an important value-creating period for Marker.
— Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
Edgen Stock·Mar 18 2026, 22:15
